CAS
SUPN icon

Coppell Advisory Solutions’s Supernus Pharmaceuticals SUPN Stock Holding History

Coppell Advisory Solutions’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-637
Closed -$23.5K – 1670
2024
Q4 		$23.5K Buy
+637
New +$22.4K ﹤0.01% 815
2023
Q4 		$17.9K Buy
619
+610
+6,778% +$16.2K ﹤0.01% 773
2023
Q3 		$321 Buy
+9
New +$274 ﹤0.01% 1072
2023
Q1 		– Sell
-9
Closed -$321 – 958
2022
Q4 		$321 Buy
+9
New +$313 ﹤0.01% 1072

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Coppell Advisory Solutions's SUPN Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Supernus Pharmaceuticals (SUPN) in Q1 2025, closing a stake of 637 shares — an estimated $23.5K sold.

Coppell Advisory Solutions first reported a position in SUPN in Q4 2022 and held it in 4 quarters. The position peaked at $23.5K in Q4 2024. 295 funds tracked by Wall St. Rank hold SUPN as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Supernus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 637 Supernus Pharmaceuticals shares in Q1 2025, an estimated $23.5K.
  • Coppell Advisory Solutions first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Coppell Advisory Solutions's Supernus Pharmaceuticals position peaked at $23.5K in Q4 2024.
  • 295 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.